Viatris Inc. (VTRS)
$
8.71
+0.03 (0.34%)
Key metrics
Financial statements
Free cash flow per share
1.6454
Market cap
10.4 Billion
Price to sales ratio
0.7036
Debt to equity
0.7677
Current ratio
1.6474
Income quality
-3.6312
Average inventory
4 Billion
ROE
-0.0325
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Viatris Inc. operates as a prominent healthcare company on a global scale, encompassing four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Offering a diverse portfolio that includes prescription brand drugs, generic medications, complex generics, biosimilars, and active pharmaceutical ingredients (APIs), the company addresses various therapeutic areas, such as noncommunicable and infectious diseases. It specializes in biosimilars across oncology, immunology, endocrinology, ophthalmology, and dermatology, while providing APIs for antibacterial agents, central nervous system medications, antihistamines, cardiovascular treatments, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Additionally, the company supports patients through diagnostic clinics, educational seminars, and digital tools aimed at improving health management. Viatris makes its medicines available in a variety of formats including oral solids, injectables, complex dosage forms, and APIs, served to retail and pharmacy networks, wholesalers and distributors, payers, insurers, governments, and institutional clients. Distribution channels encompass pharmaceutical wholesalers and distributors, retailers, institutional pharmacies, mail-order and e-commerce pharmacies, alongside specialty pharmacies. The company's well-known product lineup features Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV, in addition to biosimilars such as Fulphila, Ogivri, Hulio, and SEMGLEE. The company recorded an operating income of $10,100,000.00 reflecting its earnings from core operations. It reported a substantial revenue of $14,739,300,000.00 demonstrating its strong market presence, while the weighted average number of diluted shares outstanding is 1,193,300,000.00 which indicates potential dilution effects. The company also reported selling, general, and administrative expenses of $4,425,600,000.00 shedding light on its operational overhead costs, culminating in a diluted EPS of -$0.53 which accounts for potential share dilution. In the stock market, the company presents an attractive opportunity as the stock is affordable at $8.76 making it suitable for budget-conscious investors. It enjoys a high average trading volume of 13,331,346.00 which indicates strong liquidity within the market. With a mid-range market capitalization of $10,397,039,900.00 Viatris Inc. is recognized as a steady performer. Operating within the Drug Manufacturers - Specialty & Generic industry, it plays a crucial role in shaping the overall market landscape. Furthermore, it belongs to the Healthcare sector, actively driving innovation and growth within the healthcare field.
What is Viatris Inc. (VTRS)'s stock forecast?
Analysts predict Viatris Inc. stock to fluctuate between $8.55 (low) and $13.55 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Viatris Inc.'s market capitalization?
As of 2025-04-01, Viatris Inc.'s market cap is $10,397,039,900, based on 1,193,690,000 outstanding shares.
How does Viatris Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Viatris Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Viatris Inc. (VTRS) stock?
To buy Viatris Inc. (VTRS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for VTRS. Place an order (Market, Limit, etc.).
What is the best time to invest in Viatris Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Viatris Inc. perform in the last earnings report?
Revenue: $14,739,300,000 | EPS: -$0.53 | Growth: -1,262.28%.
Where can I find Viatris Inc.'s investor relations reports?
Visit https://www.viatris.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Viatris Inc.?
You can explore historical data from here
What is the all-time high and low for Viatris Inc. stock?
All-time high: $18.68 (2021-02-18) | All-time low: $8.42 (2022-09-27).
What are the key trends affecting Viatris Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
prnewswire.com
NEW YORK , March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
globenewswire.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
prnewswire.com
NEW YORK , March 29, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public. So What: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
prnewswire.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options If you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , March 28, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS).
See all news
